• Explore /
  • Poster
  • / Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.

Intrinsic subtypes of HER2-positive breast cancer and their associations with pathologic complete response (pCR) and outcomes: Findings from NSABP B-41, a randomized neoadjuvant trial.

Abstract Poster

Authors

Sandra Swain

Sandra M. Swain

NSABP/NRG Oncology, and Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC

Sandra M. Swain , Gong Tang , Peter C. Lucas , Andre Robidoux , David Goerlitz , Brent T. Harris , Hanna Bandos , Charles E. Geyer Jr., Priya Rastogi , Eleftherios P. Mamounas , Norman Wolmark

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT00486668

Citation

J Clin Oncol 36, 2018 (suppl; abstr 580)

DOI

10.1200/JCO.2018.36.15_suppl.580

Abstract #

580

Poster Bd #

72

Abstract Disclosures

Similar Posters

First Author: Christian F. Singer

First Author: Sandra M. Swain

First Author: Jens Bodo Huober

First Author: Kay T Yeung